Financial Performance - The company reported a revenue of ¥51,329,621.47, an increase of 9.44% compared to the same period last year[13] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was ¥3,218,083.53, reflecting a growth of 48.98% year-on-year[13] - The company's operating revenue for the reporting period was 82,042,133.18, an increase of 27.73% compared to the previous year[19] - The company reported a net profit of 3,011,597.36, a decrease of 51.01% compared to the previous year, primarily due to a lack of government subsidies received last year[22] - The total revenue for the reporting period was ¥51,329,621.47, reflecting a growth of 9.42% compared to the previous period[42] - The total revenue for the first half of 2023 was CNY 82,042,133.18, an increase from CNY 64,232,221.91 in the same period of 2022, representing a growth of approximately 27.7%[47] - The net profit for the first half of 2023 was CNY 1,059,673.99, a significant decrease from a net loss of CNY 682,378.97 in the same period of 2022[46] Profitability Metrics - The gross profit margin decreased to 24.72% from 27.87% in the previous year[5] - The gross profit margin decreased to 15.46%, down 4.89 percentage points year-on-year, attributed to changes in product sales structure[19] - The gross profit margin for self-produced products decreased by 5.39 percentage points to 14.87%[32] - The gross profit margin for the overall business was 15.46%, down 4.89 percentage points from the previous year[38] - The operating profit was 3,090,234.36, down 18.01% year-on-year, influenced by a downturn in the downstream livestock industry[21] Operating Efficiency - The net cash flow from operating activities was ¥1,999,325.39, down 92.60% from ¥27,011,084.65 in the previous year[9] - The accounts receivable turnover rate improved to 1.99 from 1.19 year-on-year[9] - The inventory turnover rate increased to 3.47 from 2.58 in the previous year[9] - The credit impairment loss increased by 429.46% to -806,471.23, due to an increase in accounts receivable and the need to provision for bad debts[19] Revenue Sources - Revenue from blood products is $48,984,385.33, compared to $36,728,640.76 in the previous period, reflecting a significant increase of approximately 33.3%[57] - Revenue from stress-resistant and appetite-inducing products decreased to $913,841.93 from $2,133,811.87, a decline of about 57.1%[57] - Revenue from technical services decreased to $116,428.00 from $1,224,145.00, a decline of about 90.5%[57] - Other business revenue increased by 21.80% to ¥93,209.02, up from ¥76,529.15[31] Strategic Initiatives - The company launched cost-reduction products for livestock farmers in response to market pressures[12] - New departments were established, including ruminant, e-commerce, aquaculture, and regional divisions, to enhance market expansion[12] - The company aims to expand its product matrix to include aquaculture and pet sectors, leveraging its patented blood product technology[15] - The company plans to expand its market presence and invest in new product development to drive future growth[46] - The company has identified strategic opportunities for mergers and acquisitions to enhance its competitive position in the market[46] Other Financial Metrics - Other income increased significantly by 725.41% to 300,210.70, mainly due to government rewards received during the period[21] - Investment income rose to 2,482,029.52, a 145.04% increase, driven by higher returns from associated companies and increased interest from large time deposits[21] - Research and development expenses for the first half of 2023 were CNY 2,137,582.81, slightly down from CNY 2,293,360.29 in the first half of 2022, reflecting a decrease of about 6.8%[47] - The total assets of the company were reported at CNY 81,864,563.44, with net assets amounting to CNY 10,739,638.46[46] Market Position - The company maintains a leading position in the industry, supported by strong brand recognition and technological advancements[15] - The sales structure of the new product series accounted for 75.17% of total sales, contributing to the decline in gross margin[38] - Revenue from the Northeast region increased by 215.13% to ¥1,709,073.60, while the gross margin was 49.47%[41] Miscellaneous - The company expressed apologies for any inconvenience caused by the corrections made to the financial report[58] - The company has not disclosed any new product launches or technological advancements during this reporting period[58] - There are no updates on market expansion or mergers and acquisitions mentioned in the conference call[58]

Financial Performance - The company's revenue for 2022 was corrected to ¥97,072.53 million, a decrease of 28.62% compared to 2021[6]. - The net profit attributable to shareholders for 2022 was corrected to ¥17,399.34 million, reflecting a decrease of 56.52% year-over-year[10]. - The gross profit margin for 2022 was adjusted to 30.56%, down from 43.98% in 2021[6]. - The basic earnings per share for 2022 was corrected to ¥0.11, a decline of 56% compared to ¥0.25 in 2021[5]. - The overall operating profit margin was reported at 12.4%, down from 31.3% in the previous year[19]. - The operating profit for the reporting period was 19.19 million, a decrease of 55.43% compared to 2021, primarily due to a smaller increase in main business income compared to the increase in operating costs[24]. - The net profit for the reporting period was 17.38 million, a decrease of 56.56% compared to 2021, influenced by multiple factors[24]. - The company reported a net profit margin impacted by increased R&D expenses and operational costs[58]. - Total operating revenue for 2022 was 97,072,539, a decrease of 28.5% compared to 135,985,501 in 2021[60]. - Net profit for 2022 was 17,382,063, representing a decline of 56.6% from 40,017,018 in 2021[62]. Cash Flow - The net cash flow from operating activities for 2022 was ¥54,469.48 million, an increase of 112% from ¥25,658.46 million in 2021[8]. - The net cash flow from operating activities was 54,469.5 million, an increase of 112.29% compared to the previous year, driven by higher sales cash ratios[35]. - The net cash flow from investing activities was -21,838.7 million, an increase of 68.51% year-on-year, mainly due to reduced fixed asset investments[35]. - The net cash flow from financing activities was -49,349.2 million, a decrease of 245.05% compared to the previous year, attributed to the absence of external financing in 2022[35]. Operating Costs and Expenses - Operating costs amounted to 67,410,728 yuan, reflecting a decrease of 11.51% from 76,174,676 yuan in the previous year[19]. - Sales expenses were 10,897,595 yuan, a reduction of 15.18% compared to 12,847,418 yuan in the previous year[19]. - The operating cost for the reporting period was 67.18 million, a decrease of 11.58% compared to 2021, mainly due to reduced sales volume of blood products[25]. - Research and development expenses increased by 19.23% to 4,749,646 yuan from 3,983,697 yuan in the previous year[19]. Revenue Sources - The revenue from hematopoietic products was 84,102.3 million, a decrease of 8.55% compared to the same period in 2021[32]. - The revenue from other products was 12,970.2 million, a decrease of 70.54% year-on-year, primarily due to a reduction in various feed materials and technical service fees[31]. - Revenue from blood products was 79,906,522.33, down from 89,420,301.90 in the previous period[64]. - Revenue from stress-resistant and appetite-inducing products was 4,195,808.87, an increase from 2,543,664.50 in the previous period[64]. - Revenue from concentrated feed and additives was 8,702,552.93, down from 30,976,376.37 in the previous period[64]. Audit and Compliance - The company identified revenue recognition as a key audit matter due to the inherent risk of management manipulating revenue recognition timing[48]. - The company has implemented significant audit procedures to evaluate the effectiveness of internal controls related to revenue recognition[49]. - The company's revenue recognition policy aligns with accounting standards, ensuring compliance[55]. - The company’s management has been proactive in addressing potential risks associated with revenue recognition practices[48]. Subsidiaries and Investments - The company has four wholly-owned subsidiaries, one controlling subsidiary, and one associated company as of December 31, 2022[42]. - Guangzhou Sanhang Biotechnology Co., Ltd. generated revenue of 3.76 million yuan and a net profit of 0.55 million yuan during the reporting period[42]. - Guangzhou Sanhang Feed Co., Ltd. achieved revenue of 11.83 million yuan and a net profit of 0.87 million yuan[45]. - Guangdong Sanhang Biotechnology Co., Ltd. reported revenue of 37.09 million yuan and a net profit of 0.31 million yuan[45]. - Guangzhou Saitao Flower Biotechnology Co., Ltd. generated revenue of 2.56 million yuan and a net profit of 1.37 million yuan[45]. - Guangdong Sanhang Blood Feed Co., Ltd. reported a net loss of 0.035 million yuan during the reporting period[43]. - Guangdong Xinnandu Feed Technology Co., Ltd. achieved revenue of 55.96 million yuan and a net profit of 5.46 million yuan[45]. Management Commentary - The company expressed apologies for any inconvenience caused by the corrections made in the financial report[65]. - The company plans to expand its market presence and enhance product offerings through new technology development and strategic partnerships[30].

2023 年度独立董事述职报告（李平） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：838275 证券简称：驱动力 公告编号：2024-026 广东驱动力生物科技集团股份有限公司 本人李平自 2023 年 11 月 16 日起担任广东驱动力生物科技集团股份有限公 司(以下简称"公司") 的独立董事，在任职期间严格按照《公司法》《证券法》 《上市公司独立董事管理办法》《北京证券交易所股票上市规则（试行）》《北京 证券交易所上市公司持续监管指引第 1 号——独立董事》、等法律法规的规定以 及《公司章程》和《独立董事工作制度》的要求，谨慎、认真、勤勉、独立地履 行职责，持续关注公司规范运作、重大生产经营活动、财务状况等，积极出席 2023 年度的相关会议，认真审议各项议案，对重大事项发表了独立意见，维护了公司 整体利益和全体股东尤其是中小股东的合法权益。 现就 2023 年度任职期间内履行职责情况汇报如下： 一、独立董事独立性情况 作为公司的独立董事，本人及本人直系亲属均不在公司或其附属企业担任 ...

证券代码：838275 证券简称：驱动力 公告编号：2024-018 广东驱动力生物科技集团股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 本公司于 2020 年 12 月 25 日收到中国证券监督管理委员会下发的《关于核 准广东驱动力生物科技股份有限公司向不特定合格投资者公开发行股票的批复》 （证监许可）【2020】3625 号），核准公司向不特定合格投资者公开发行不超过 1,200 万股新股（含行使超额配售选择权所发新股）。公司本次发行的价格为 5.00 元/股，发行股数 1,200 万股（含行使超额配售选择权所发行的股份），实际募集 资金 60,000,000.00 元（超额配售选择权行使后），扣除发行费用人民币 11,800,066.04 元（不含税）后，募集资金净额为人民币 48,199,933.96 元。截 止 2021 年 2 月 24 日，上述募集资金已全部到账，经大华会计师事务所（特殊普 通合伙）验资，并由其出具 ...

广东驱动力生物科技集团股份有限公司 证券代码：838275 证券简称：驱动力 公告编号：2024-010 第三届监事会第十四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 会议召开符合《公司法》等法律、法规及本公司章程的有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于 2023 年度监事会工作报告的议案》 1.议案内容： 监事会对 2023 年的监事会工作做了总结。主要概述了 2023 年度监事会重点 工作完成情况并明确了 2024 年度监事会的重点工作。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 （一）会议召开情况 1.会议召开时间：2024 年 4 月 25 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2024 年 4 月 12 日以信息及书面方式发出 5.会议主持人：监事会主席全渺晶 6.召开情况合法、合规、合 ...

一、募集资金基本情况 驱动力于 2020 年 12 月 25 日收到中国证券监督管理委员会下发的《关于核 准广东驱动力生物科技股份有限公司向不特定合格投资者公开发行股票的批复》 （证监许可【2020】3625 号），核准公司向不特定合格投资者公开发不超过 1,200 万股新股（含行使超额配售选择权所发新股）。公司本次发行的价格为 5 元/股，发行股数 1,200 万股新股（含行使超额配售选择权所发的股份），实际 募集资金 60,000,000.00 元（超额配售选择权行使后），扣除发行费用人民币 11,800,066.04(不含税)后，上述募集资金已全部到账，经大华会计师事务所 （特殊普通合伙）验证，并由其出具"大华验字[2021]000015 号和大华验字 [2021]000122 号"验资报告。 华安证券股份有限公司 关于广东驱动力生物科技集团股份有限公司 使用部分闲置募集资金进行现金管理的专项核查意见 华安证券股份有限公司（以下简称"华安证券"或"保荐机构"）作为广东 驱动力生物科技集团股份有限公司（以下简称"驱动力"或"公司"）向不特定 合格投资者公开发行股票并在北交所上市的保荐机构，根据《证券发行上 ...

广东驱动力生物科技集团股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：838275 证券简称：驱动力 公告编号：2024-016 （二）监事会意见 基于综合考虑公司未来发展规划以及保证公司正常经营资金的需要，董事会 拟定公司 2023 年度利润分配预案。 一、权益分派预案情况 根据公司 2024 年 4 月 29 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 17,931,292.01 元，母公司未分配利润为 12,331,220.90 元。 公司本次权益分派预案如下：公司目前总股本为 160,277,600 股，根据扣除 回购专户 900,000 股后的 159,377,600 股为基数，以未分配利润向全体股东每 10 股派发现金红利 0.30 元（含税）。本次权益分派共预计派发现金红利 4,781,328.00 元；不送红股，不以公积金转增股本。 公司 ...

北京市中伦（广州）律师事务所 关于广东驱动力生物科技集团股份有限公司 2022 年股权激励计划 注销部分已获授但尚未行权的股票期权的 法律意见书 二〇二四年四月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 中伦是一家特殊的普通合伙制律师事务所 Zhong Lun is formed as an LLP under PRC law. 广东省广州市天河区珠江新城华夏路 10 号富力中心 23 楼整层及 31 楼 01、04 单元 邮编：510623 23/F, Units 01 & 04 of 31/ ...

证券代码：838275 证券简称：驱动力 公告编号：2024-011 广东驱动力生物科技集团股份有限公司前期会计差错更 正公告 广东驱动力生物科技集团股份有限公司（以下简称"公司"）出于谨慎性考 虑，对相关业务按照净额法确认收入。 根据财政部《企业会计准则第 28 号——会计政策、会计估计变更和差错更 正》和中国证券监督管理委员会《公开发行证券的公司信息披露编报规则第 19 号——财务信息的更正及相关披露》的相关规定，经审慎审查，公司对前期财务 报表差错予以更正。 二、表决和审议情况 公司于 2024 年 4 月 25 日召开第三届董事会第十六次会议、第三届监事会第 十四次会议，分别审议通过了《关于前期会计差错更正及追溯调整的议案》，并 同意将议案提交公司股东大会审议。 三、董事会关于本次会计差错更正合理性的说明 公司董事会认为：本次会计差错更正符合《企业会计准则第 28 号—会计政 策、会计估计变更和差错更正》、《公开发行证券的公司信息披露编报规则第 19 号—财务信息的更正及相关披露》等相关文件的规定，更正后能够提供更可靠的 会计信息，有利于更加客观、公允反映公司财务状况，符合相关规定和公司实际 情况，不 ...

华安证券股份有限公司 关于广东驱动力生物科技集团股份有限公司 2023 年募集资金存放及使用情况的专项核查报告 华安证券股份有限公司(以下简称"华安证券"、"保荐机构")为广东驱动 力生物科技集团股份有限公司(以下简称"驱动力"或"公司")向不特定合 格投资者公开发行股票的保荐机构。根据《北京证券交易所股票上市规则(试 行)》《上市公司监管指引第 2 号-上市公司募集资金管理和使用的监管要求 (2022 年修订)》等有关法律法规和规范性文件要求，对公司 2023 年度募集 资金存放与使用情况进行了核查，具体情况如下： 一、公司募集资金基本情况 公司于 2020 年 12 月 25 日收到中国证券监督管理委员会下发的《关于 核准广东驱动力生物科技股份有限公司向不特定合格投资者公开发行股票的 批复》（证监许可【2020】3625 号）,核准公司向不特定合格投资者公开发 行不超过 1,200 万股新股(含行使超额配售选择权所发新股)。 公司本次发行的价格为 5.00/股，发行股数 1,200 万股(含行使超额配 售选择权所发的股份),实际募集资金 60,000,000 元(超额配售选择权行使 后)，扣除发行费用人民 ...